In November 2016, PacBio filed a Complaint with the International Trade Commission (“ITC”) alleging that Oxford Nanopore infringed two of PacBio’s patents and seeking to prevent Oxford Nanopore from selling its product in the United States. 

Today, the ITC Commission has made a Final Determination affirming the Administrative Judge’s decision that Oxford Nanopore has not infringed PacBio’s patents. The ITC Commission also found that there has been no violation of 19 U.S.C. §1337 and terminated the ITC investigation.

Gordon Sanghera, CEO of Oxford Nanopore, said: “We are pleased that Pacific Biosciences has failed, in this action, to prevent Americans choosing and benefiting from Nanopore single molecule, real time DNA sequencing”.